“With the approval of DYNEX AGILITY, we now offer a fully automated solution for high-volume immunoassay testing in the rapidly growing in-vitro diagnostics (IVD) market in China,” commented David Sholehvar, M.D., Chief Executive Officer, of Dynex Technologies. “As an open platform, AGILITY allows our customers to select the assays which work best for them across many disease states. This enables labs to meet increased testing demands from the growth in aging populations and subsequent increase in diagnostic needs for chronic and infectious diseases, as well as cancer and other important disease states.”
With an instrument base of over 7,500 systems globally, Dynex has a proven track record of quality, acceptance, and success in automating clinical laboratories. Designed with the automated laboratory in mind, DYNEX AGILITY can increase the laboratory productivity by increasing throughput while also reducing labor and consumable spending. Agility's streamlined front-end preparation minimizes hands-on reagent loading versus traditional open systems, reducing overall assay processing times.
About DYNEX Technologies (www.dynex.com): DYNEX® is an original pioneer and market leader in automated microplate technology. Our talented, multidisciplinary staff of approximately 140 people worldwide include design and service engineers, applications scientists, marketing, sales specialists, and precision-manufacturing experts. We are dedicated to perpetual innovation in product design and new applications frontiers to deliver cutting-edge microplate processing systems that meet the rigorous demands of the most challenging applications, which ultimately improve health outcomes and enhance life. Contact us at (703) 631-7800 or email@example.com.